Mondaq Canada: Food, Drugs, Healthcare, Life Sciences
Norton Rose Fulbright Canada LLP
The 322 Patent claims compositions of ciclesonide with varying osmotic pressures, ranging from 10 mOsm or less to 290 mOsm or less.
TTL Health Law
In a blog post last August, I discussed the heated debate that was taking place regarding whether doctors should be allowed to refuse treatment on moral or religious ground.
McCarthy Tétrault LLP
If implemented, the tariffs are likely to impact the highly-integrated North American agri-food supply chain, affecting industry players on both sides of the border.
Norton Rose Fulbright Canada LLP
On April 20, 2015, the Quebec National Assembly passed Bill 28, An Act mainly to implement certain provisions of the Budget Speech of 4 June 2014 and return to a balanced budget in 2015-2016 (Bill), which was tabled in November 2014 by the Minister of Finance, Mr. Carlos Leitao.
Borden Ladner Gervais LLP
JJ, an 11 year old Mohawk girl was diagnosed with acute lymphoblastic leukemia (ALL). JJ's mother, DH, is her substitute decision maker (SDM).
Norton Rose Fulbright Canada LLP
Les nouvelles trousses diagnostiques prennent plusieurs années à être peaufinées avant d’être mises sur le marché.
TTL Health Law
As if we didn’t already have enough on our plates, the Toronto Star now wants us to add, Serve as judge and jury when doctors mess up to our list of things to do.
Norton Rose Fulbright Canada LLP
Proposed Regulations Amending the Patented Medicines (Notice of Compliance) Regulations, Canada Gazette, Part I, Vol. 149, No. 18
Miller Thomson LLP
Significant amendments to the federal Food and Drugs Act, which are commonly referred to as "Vanessa’s Law", became law in November, 2014.
Norton Rose Fulbright Canada LLP
On April 20, 2015, the Supreme Court of Canada (SCC) heard Sanofi-Aventis’ appeal of the Federal Court of Appeal section 8 quantification decision with respect to the drug Ramipril.
Gowling Lafleur Henderson LLP
On April 20, 2015, the Supreme Court of Canada dismissed Sanofi-Aventis’ appeal concerning a claim by Apotex for section 8 damages under the Patented Medicines (Notice of Compliance) Regulations.
Norton Rose Fulbright Canada LLP
Teva Canada Innovation and Teva Pharmaceutical Industries Ltd. v. Apotex Inc., 2014 FC 1070
MNP
Running a successful and profitable agri-food business in today’s increasingly complex and integrated marketplace is a huge challenge.
McCarthy Tétrault LLP
In reasons dated February 26, 2015, Justice Barnes dismissed Janssen’s application for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Teva for the compound bortezomib.
Torys LLP
Industry Canada has announced that the Patent Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations) will be amended...
Norton Rose Fulbright Canada LLP
Bill C-17, An Act to Amend the Food and Drugs Act (also referred to as the Protecting Canadians from Unsafe Drugs Act), received Royal Assent on November 6, 2014.
Stikeman Elliott LLP
On March 10, 2015, the Standing Senate Committee on Social Affairs, Science and Technology released a final report entitled "Prescription Pharmaceuticals in Canada".
Clark Wilson LLP
The Supreme Court of Canada recently revisited euthanasia, and endorsed a permissive regime that will allow doctor assisted suicide in certain limited cases.
Dickinson Wright PLLC
Back in 2012, the Ontario Court of Appeal recognized the tort of invasion of privacy – fast forward to the recent string of privacy breaches of personal information held by health care facilities in Ontario.
Gowling Lafleur Henderson LLP
The recent legislative amendments gave Health Canada new powers to address health and safety concerns regarding "therapeutic products" (which includes both drugs and medical devices...
Latest Video
Most Popular Recent Articles
Moodys Gartner Tax Law LLP
Budget announcements from the Government of Alberta for the last number of years have generally been humdrum events.
Torys LLP
Manufacturers and distributors intending to market their U.S. dietary supplements in Canada will want to understand the regulation of dietary supplements in the U.S.
McCarthy Tétrault LLP
Although PHIPA was introduced over ten years ago, only one person has ever been charged under the legislation...
McCarthy Tétrault LLP
In reasons dated February 26, 2015, Justice Barnes dismissed Janssen’s application for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Teva for the compound bortezomib.
McCarthy Tétrault LLP
If implemented, the tariffs are likely to impact the highly-integrated North American agri-food supply chain, affecting industry players on both sides of the border.
Gowling Lafleur Henderson LLP
On April 20, 2015, the Supreme Court of Canada dismissed Sanofi-Aventis’ appeal concerning a claim by Apotex for section 8 damages under the Patented Medicines (Notice of Compliance) Regulations.
Smart & Biggar/Fetherstonhaugh
Health Canada has recently released a draft Good Label and Package Practices Guide for stakeholder consultation.
Borden Ladner Gervais LLP
JJ, an 11 year old Mohawk girl was diagnosed with acute lymphoblastic leukemia (ALL). JJ's mother, DH, is her substitute decision maker (SDM).
Gowling Lafleur Henderson LLP
Prince Edward Island, the Northwest Territories and the Yukon have introduced new legislation aimed at protecting personal health information that is expected to come into force sometime in 2015.
Affleck Greene McMurtry LLP
Although only the OTC joint venture was notifiable under Part IX of the Competition Act, the Bureau conducted a full analysis on all three parts of the proposed transaction.
Article Search Using Filters
Related Topics
Mondaq Advice Centre (MACs)
Popular Authors
Popular Contributors
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
Partners